GlassScriptPhysician profile
Samiya Mohiuddin
NPI 1912536186
$4,477.58
in general payments reported to CMS, 2019-2025
26 companies · $1,079 in 2025
The $1,079 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $775 · 2023: $1,050 · 2024: $1,239 · 2025: $1,079.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,168 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,167.52 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $942.03 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $591.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $570.63 | 2021-2025 | |
| Astellas Pharma US INC | $357.04 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.23 | 2022-2025 | Jardiance |
| Pfizer INC. | $269.52 | 2022-2025 | |
| Lilly USA, LLC | $258.41 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Glaxosmithkline, LLC. | $218.17 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $183.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.66 | 2022-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $94.21 | 2023-2025 | Camzyos, Eliquis |
| Ani Pharmaceuticals, INC. | $81.71 | 2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $70.76 | 2022-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $60.12 | 2022-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $52.28 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.44 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $46.05 | 2025 | Gvoke Hypopen |
| Supernus Pharmaceuticals, INC. | $43.88 | 2024 | Qelbree |
| Merck Sharp & Dohme LLC | $31.23 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $20.86 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.04 | 2023 | Trintellix |
| Alkermes, INC. | $18.84 | 2023 | Vivitrol |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2021 | |
| Amgen INC. | $16.35 | 2024 | Krystexxa |
| Tactile Systems Technology INC | $13.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samiya Mohiuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.